Lentigo Maligna

Article

San Francisco - In the United States surgery is the modality of choice for treatment of most primary as well as many recurrent lentigo maligna (LM), but there are a number of alternative options to consider for unresectable lesions, Glenn D. Goldman, M.D., said at the annual meeting of the American Academy of Dermatology.

Related Videos
Related Content

Pointers With Portela: Careers With an Increased Skin Cancer Risk

October 4th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Utilizing Naturally Occurring Compounds for Treatment of Coexisting Vitiligo and Psychiatric Conditions

October 4th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Why This Renowned Dermatologist Chooses This Neurotoxin

October 4th 2023

Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients

October 3rd 2023

Pointers With Portela: Careers With an Increased Skin Cancer Risk

October 4th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Utilizing Naturally Occurring Compounds for Treatment of Coexisting Vitiligo and Psychiatric Conditions

October 4th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Why This Renowned Dermatologist Chooses This Neurotoxin

October 4th 2023

Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients

October 3rd 2023

Pointers With Portela: Careers With an Increased Skin Cancer Risk

October 4th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Utilizing Naturally Occurring Compounds for Treatment of Coexisting Vitiligo and Psychiatric Conditions

October 4th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Why This Renowned Dermatologist Chooses This Neurotoxin

October 4th 2023

Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients

October 3rd 2023
© 2023 MJH Life Sciences

All rights reserved.